Tackling unmet needs in lymphoma
Developments that are changing the treatment of CLL - current and future drugs
Is venetoclax appropriate for relapsed CLL patients?
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
Final results of the AIM study of ibrutinib and venetoclax in mantle cell lymphoma